Table 3.
Characteristics of endometriosis group in the training and validation cohorts.
| Training cohort | Validation cohort | p-Value | |
|---|---|---|---|
| Patients | 363 | 178 | |
| Female age (years) | 30.78 ± 4.05 | 30.96 ± 4.43 | 0.631 |
| Male age (years) | 31.82 ± 4.70 | 31.86 ± 4.87 | 0.934 |
| Female BMI (kg/m2) | 22.04 ± 3.17 | 22.18 ± 3.16 | 0.612 |
| Infertility duration (months) | 41.72 ± 32.18 | 38.71 ± 29.63 | 0.295 |
| AMH (ng/ml) | 3.02 ± 2.40 | 3.02 ± 2.09 | 0.983 |
| Basal FSH (mIU/ml) | 6.97 ± 2.10 | 7.11 ± 2.69 | 0.500 |
| Basal LH (mIU/ml) | 5.54 ± 5.13 | 5.93 ± 6.11 | 0.437 |
| Gonadotrophin duration (days) | 13.12 ± 1.95 | 13.21 ± 1.98 | 0.618 |
| Gonadotrophin dosage (IU) | 2,604.65 ± 1,036.67 | 2,572.75 ± 1,016.47 | 0.735 |
| Oocytes retrieved | 13.58 ± 6.60 | 14.42 ± 6.83 | 0.171 |
| Fertilization rate (%) | 66.10 ± 18.11 | 66.77 ± 18.18 | 0.684 |
| Cleavage rate (%) | 99.12 ± 3.14 | 98.49 ± 4.58 | 0.097 |
| Top day 3 embryo rate (%) | 61.32 ± 27.55 | 59.37 ± 27.67 | 0.441 |
| Blastulation rate (%) | 44.06 ± 35.50 | 43.45 ± 35.70 | 0.849 |
| High-quality blastulation rate (%) | 12.10 ± 20.70 | 12.15 ± 21.20 | 0.979 |
| Embryo utilization rate (%) | 56.50 | 56.48 | 0.990 |
| Average number of ET | 1.74 ± 0.44 | 1.72 ± 0.45 | 0.581 |
| Embryo implantation rate (%) | 47.78 | 42.91 | 0.210 |
| Clinical pregnancy rate (%) | 62.81 | 54.86 | 0.112 |
| Live birth rate (%) | 46.31 | 41.67 | 0.360 |
Numbers are means ± SD. Basal FSH and LH were measured between the second and third days of female menstrual cycle. No significant difference was found between the training and validation cohorts in the three groups. When p-value is 0.05, we consider it to be significant.
ET, embryo transfer; BMI, body mass index; AMH, anti-Mullerian hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone.